273 related articles for article (PubMed ID: 36050227)
1. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
Butt JH; Dewan P; Jhund PS; Anand IS; Atar D; Ge J; Desai AS; Echeverria LE; Køber L; Lam CSP; Maggioni AP; Martinez F; Packer M; Rouleau JL; Sim D; Van Veldhuisen DJ; Vrtovec B; Zannad F; Zile MR; Gong J; Lefkowitz MP; Rizkala AR; Solomon SD; McMurray JJV
J Am Coll Cardiol; 2022 Sep; 80(12):1130-1143. PubMed ID: 36050227
[TBL] [Abstract][Full Text] [Related]
2. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
McMurray JJV; Jackson AM; Lam CSP; Redfield MM; Anand IS; Ge J; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Rizkala AR; Sabarwal SV; Shah AM; Shah SJ; Shi VC; van Veldhuisen DJ; Zannad F; Zile MR; Cikes M; Goncalvesova E; Katova T; Kosztin A; Lelonek M; Sweitzer N; Vardeny O; Claggett B; Jhund PS; Solomon SD
Circulation; 2020 Feb; 141(5):338-351. PubMed ID: 31736337
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E;
J Am Coll Cardiol; 2023 Jul; 82(1):1-12. PubMed ID: 37212758
[TBL] [Abstract][Full Text] [Related]
5. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
6. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
[TBL] [Abstract][Full Text] [Related]
7. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
Curtain JP; Adamson C; Docherty KF; Jhund PS; Desai AS; Lefkowitz MP; Rizkala AR; Rouleau JL; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJV
JACC Heart Fail; 2023 Jul; 11(7):749-759. PubMed ID: 37407154
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
Vaduganathan M; Mentz RJ; Claggett BL; Miao ZM; Kulac IJ; Ward JH; Hernandez AF; Morrow DA; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Lefkowitz M; McMurray JJV; Braunwald E; Solomon SD
Eur Heart J; 2023 Aug; 44(31):2982-2993. PubMed ID: 37210743
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
10. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial.
Ostrominski JW; Claggett BL; Packer M; Pfeffer MA; Lam CSP; Zile MR; Desai AS; Jhund PS; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
J Card Fail; 2023 Nov; 29(11):1494-1503. PubMed ID: 37220823
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
12. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial.
Desai AS; Vaduganathan M; Cleland JG; Claggett BL; Barkoudah E; Finn P; McCausland FR; Yilmaz MB; Lefkowitz M; Shi V; Pfeffer MA; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Dec; 14(12):e008597. PubMed ID: 34807713
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial.
Chatur S; Vaduganathan M; Peikert A; Claggett BL; McCausland FR; Skali H; Pfeffer MA; Beldhuis IE; Kober L; Seferovic P; Lefkowitz M; McMurray JJV; Solomon SD
Eur J Heart Fail; 2022 Oct; 24(10):1906-1914. PubMed ID: 35895867
[TBL] [Abstract][Full Text] [Related]
14. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
15. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
16. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial.
Jering K; Claggett B; Redfield MM; Shah SJ; Anand IS; Martinez F; Sabarwal SV; Seferović PM; Kerr Saraiva JF; Katova T; Lefkowitz MP; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2021 May; 9(5):386-397. PubMed ID: 33714741
[TBL] [Abstract][Full Text] [Related]
17. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Vaduganathan M; Cunningham JW; Claggett BL; Causland FM; Barkoudah E; Finn P; Zannad F; Pfeffer MA; Rizkala AR; Sabarwal S; McMurray JJV; Solomon S; Desai AS
JACC Heart Fail; 2021 May; 9(5):374-382. PubMed ID: 33839075
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.
Cunningham JW; Claggett BL; O'Meara E; Prescott MF; Pfeffer MA; Shah SJ; Redfield MM; Zannad F; Chiang LM; Rizkala AR; Shi VC; Lefkowitz MP; Rouleau J; McMurray JJV; Solomon SD; Zile MR
J Am Coll Cardiol; 2020 Aug; 76(5):503-514. PubMed ID: 32731928
[TBL] [Abstract][Full Text] [Related]
19. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
Peikert A; Vaduganathan M; Mc Causland F; Claggett BL; Chatur S; Packer M; Pfeffer MA; Zannad F; Lefkowitz MP; Pieske B; Düngen HD; McMurray JJV; Solomon SD
Eur J Heart Fail; 2022 May; 24(5):794-803. PubMed ID: 35119183
[TBL] [Abstract][Full Text] [Related]
20. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
Chatur S; Claggett BL; McCausland FR; Rouleau J; Zile MR; Packer M; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
J Am Coll Cardiol; 2023 Apr; 81(15):1443-1455. PubMed ID: 36812948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
